{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:58:58Z","timestamp":1760403538773,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007707","name":"University of California, Davis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007707","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012807","name":"Midwestern University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ijantimicag.2020.105964","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T20:38:53Z","timestamp":1585946333000},"page":"105964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2871-1923","authenticated-orcid":false,"given":"Mark","family":"Olsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanthida","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.105964_bib0001","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.vetmic.2018.04.026","article-title":"The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies","volume":"219","author":"Murphy","year":"2018","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0002","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.vetmic.2014.10.025","article-title":"Levels of feline infectious peritonitis virus in blood, effusions, and various tissues and the role of lymphopenia in disease outcome following experimental infection","volume":"175","author":"Pedersen","year":"2015","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0003","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3201\/eid1907.121094","article-title":"Mutation in spike protein cleavage site and pathogenesis of feline coronavirus","volume":"19","author":"Licitra","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0004","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0005","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/1098612X17729626","article-title":"Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis","volume":"20","author":"Pedersen","year":"2018","journal-title":"J Feline Med Surg"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in favour of remdesivir for treating SARS-CoV-2 infections","author":"Ko","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.micinf.2020.03.003","article-title":"Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2","author":"Qiu","year":"2020","journal-title":"Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0008","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0009","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1128\/JVI.00737-08","article-title":"Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2","volume":"82","author":"Netland","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0010","article-title":"The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients","author":"Li","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0011","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.antiviral.2018.10.025","article-title":"Novel amodiaquine derivatives potently inhibit Ebola virus infection","volume":"160","author":"Sakurai","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0012","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2217\/14622416.8.2.187","article-title":"CYP2C8 and antimalaria drug efficacy","volume":"8","author":"Gil","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0013","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0014","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104547","article-title":"Chloroquine inhibits endosomal viral RNA release and autophagy-dependent viral replication and effectively prevents maternal to fetal transmission of Zika virus","volume":"169","author":"Zhang","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0016","doi-asserted-by":"crossref","first-page":"e00293","DOI":"10.1002\/prp2.293","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","author":"Al-Bari","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0017","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.bbrc.2019.11.065","article-title":"Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities","volume":"522","author":"Du","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0018","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0019","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350400900115","article-title":"Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis","volume":"9","author":"Witvrouw","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0020","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bbrc.2004.04.083","article-title":"HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus","volume":"318","author":"Yamamoto","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0021","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.antiviral.2010.06.010","article-title":"Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus","volume":"88","author":"Hsieh","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0022","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00280-012-1961-4","article-title":"Phase I study of nelfinavir in liposarcoma","volume":"70","author":"Pan","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25729","article-title":"A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus\u2014a possible reference for coronavirus disease-19 treatment option","author":"Yao","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0024","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.3204","article-title":"Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore","author":"Young","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2020.105964_bib0025","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","author":"Cao","year":"2020","journal-title":"N Engl J Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920301217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920301217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:37:20Z","timestamp":1760377040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920301217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0924857920301217"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105964","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105964"}}